Care Coordination to Reduce Hospital Readmissions for Heart Failure and Heart Attack
This study is looking at a care coordination program called COMPASSION Digital Biomarker to see if it can help reduce hospital readmissions for people with heart failure (HF) or who have had an acute myocardial infarction (heart attack). The COMPASSION Digital Biomarker uses data from vital signs collected by a system called Vitalbeat workbench to guide care. You may be able to join if you are 18 or older and have been hospitalized with a primary diagnosis of acute decompensated heart failure (ADHF) or an acute myocardial infarction. Success in this study means seeing a reduction in readmissions within 30 days. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 1000 participants. The study does not specify if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal is to reduce readmissions, which will be measured at 30 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions
At a glance
Conditions
NCT04905160
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Multiple Locations
Phoenix, Arizonano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Kris Vijay, MD · STUDY_CHAIR · Abrazo Arizona Heart
- Raj Bhat, MD · STUDY_DIRECTOR · Pioneer Hospitalists
- Zaki Lababidi, MD · PRINCIPAL_INVESTIGATOR · Gilbert Cardiology
- Ashok Solsi, MD · PRINCIPAL_INVESTIGATOR · Premier Cardiovascular Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Reducing readmissions30 days
The primary objective of this study is to evaluate the efficacy of treatment strategy in reducing readmissions based on the COMPASSION algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment. Improvement of patient outcomes will be measured by reduction of composite of HF re-hospitalization and all-cause mortality through 30 days in patients with recent acute Myocardial Infarction and recent admission for decompensated heart failure.